CD24 and benign prostatic hyperplasia: In light of these considerations, this study aims to bridge existing gaps in knowledge by thoroughly examining the expression of the CD24 marker and its nuanced relationship with benign prostatic hyperplasia and Gleason grade in prostate adenocarcinoma.